Ozempic is not FDA-approved for prediabetes, which means most insurance plans will not cover it for that diagnosis alone. The drug is approved specifically for type 2 diabetes, and insurers typically follow FDA-approved indications when deciding what to pay for. That said, there are some paths to coverage depending on your insurance type, your other health conditions, and whether your doctor can make a case for an alternative diagnosis.
Why Prediabetes Isn’t a Covered Indication
Ozempic (semaglutide) has three FDA-approved uses: improving blood sugar control in adults with type 2 diabetes, reducing the risk of major cardiovascular events in adults with type 2 diabetes and heart disease, and protecting kidney function in adults with type 2 diabetes and chronic kidney disease. Prediabetes does not appear anywhere on the label.
This distinction matters because insurance companies base their formulary decisions on FDA approvals. When your doctor submits a prescription with a prediabetes diagnosis code, the claim will almost certainly be rejected. Without type 2 diabetes on the paperwork, there is no standard coverage pathway for Ozempic through most commercial, Medicare, or Medicaid plans.
The Catch-22 of Prevention
There is a well-known frustration in this space: the drug that could help prevent someone from progressing to type 2 diabetes often isn’t covered until they actually develop the condition. One case highlighted by WebMD illustrates this perfectly. A patient with prediabetes caused or worsened by excess weight was eventually prescribed Ozempic, but only after his condition qualified as type 2 diabetes. The prediabetes diagnosis alone would not have been enough to get insurance approval.
This creates a situation where patients and doctors sometimes wait for the condition to worsen before the most effective treatments become accessible. It is one of the more contentious issues in how insurers handle preventive care for metabolic conditions.
What Medicare Is Doing Differently
Starting July 1, 2026, Medicare is launching a pilot program called the “Medicare GLP-1 Bridge” that explicitly includes prediabetes as a qualifying condition, though not for Ozempic specifically. The program covers Wegovy (which contains the same active ingredient as Ozempic, semaglutide, at a higher dose), Zepbound, and Foundayo for weight reduction.
To qualify, a Medicare beneficiary needs a BMI of 27 or higher and a diagnosis of prediabetes (as defined by American Diabetes Association guidelines), a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. The copay under this program is $50 per month. The demonstration runs through December 31, 2027.
There is an important caveat: if your doctor prescribes an eligible GLP-1 drug for a use already coverable under standard Medicare Part D (like type 2 diabetes), you would not qualify for the bridge program. It is designed specifically for weight-related prescribing in people who don’t yet have diabetes.
Medicaid and State-Level Coverage
Medicaid programs are required to cover GLP-1 drugs for diabetes, cardiovascular disease, and obstructive sleep apnea. Coverage for obesity treatment, however, is optional. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service. Four states (California, New Hampshire, Pennsylvania, and South Carolina) recently eliminated that coverage, and several others are considering restrictions due to cost concerns.
For prediabetes specifically, there is no Medicaid mandate. If your state does cover GLP-1s for obesity and you meet weight-related criteria, your doctor may be able to frame the prescription around a weight management indication rather than prediabetes. But this depends entirely on your state’s policies and whether the specific drug has an FDA-approved obesity indication (Ozempic does not; Wegovy does).
Employer Insurance Plans
Employer-sponsored plans vary widely. Among large employers with 5,000 or more employees, 66% reported that covering GLP-1s for weight loss had a significant impact on their drug spending. In 2025, GLP-1 prescriptions for weight loss represented over 10% of all annual prescription drug claims among employer plans. This cost pressure is pushing some employers to restrict or drop GLP-1 coverage for weight-related conditions entirely.
Even if your employer plan covers GLP-1 medications, the coverage likely requires a type 2 diabetes diagnosis for Ozempic specifically. Some plans may cover Wegovy for weight management with a prior authorization, which could be an alternative route if you have a qualifying BMI.
What Ozempic Costs Without Coverage
Without insurance, a month’s supply of Ozempic runs between $1,000 and $1,400. With insurance that does cover it (typically for type 2 diabetes), the monthly cost ranges from $25 to $200. For comparison, metformin, the most commonly prescribed medication for prediabetes prevention, costs about $4 a month with insurance and $4 to $15 without it.
Novo Nordisk offers a savings card that brings the cost down to $25 per fill, but you need commercial insurance that already covers the prescription. The company also has a Patient Assistance Program for people on Medicare or without insurance whose household income is at or below 400% of the federal poverty level. Neither program lists prediabetes as a qualifying diagnosis, since both are tied to Ozempic’s approved uses.
Practical Options if You Have Prediabetes
If your doctor believes a GLP-1 medication would benefit you, there are a few realistic paths forward. The most straightforward is metformin, which is widely prescribed for prediabetes prevention, costs very little, and does not face the same insurance barriers. The American Diabetes Association’s guidelines support its use for prediabetes.
If weight loss is a primary goal and you have a BMI of 27 or higher with a weight-related complication (or 30 or higher without one), your doctor might prescribe Wegovy instead of Ozempic. Wegovy contains the same drug at a higher dose but is FDA-approved for weight management, which gives insurers a covered indication to work with. Coverage is still not guaranteed, and many insurers restrict it or require prior authorization, but it is a more viable path than trying to get Ozempic approved for prediabetes.
Some doctors also pursue prior authorization or formulary exception requests, making a clinical argument that the medication is medically necessary for a specific patient. Success rates vary by insurer, and the process can take weeks. If your prediabetes coexists with obesity or cardiovascular risk factors, the case becomes stronger, particularly if you have documented failed attempts at lifestyle modification.
For Medicare beneficiaries, the GLP-1 Bridge program launching in mid-2026 represents the first direct coverage pathway for people with prediabetes to access semaglutide (through Wegovy) at a predictable $50 monthly copay.